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Ghrelin secretion has been reportedly increased by fasting
and energy restriction but decreased by food intake, glucose,
insulin, and somatostatin. However, its regulation is still far
from clarified. The cholinergic systemmediates some ghrelin
actions, e.g. stimulation of gastric contractility and acid se-
cretion and its orexigenic activity. To clarify whether ghrelin
secretion undergoes cholinergic control in humans, we stud-
ied the effects of pirenzepine [PZ, 100 mg per os (by mouth)],
a muscarinic antagonist, or pyridostigmine (PD, 120 mg per
os), an indirect cholinergic agonist, on ghrelin, GH, insulin,
and glucose levels in six normal subjects. PD increased (P <
0.05) GH (change in area under curves, mean  SEM, 790.9 
229.3 gmin/liter) but did not modify insulin and glucose
levels.PZdidnot significantlymodifyGH, insulin, andglucose
levels. Circulating ghrelin levels were increased by PD
(11,290.5  6,688.7 pgmin/ml; P < 0.05) and reduced by PZ
(23,205.0  8,959.5 pgmin/ml; P < 0.01). The PD-induced
ghrelin peak did not precede that of GH. In conclusion, cir-
culating ghrelin levels in humans are increased and reduced
by cholinergic agonists and antagonists, respectively. Thus,
ghrelin secretion is under cholinergic, namely muscarinic,
control inhumans. Thevariations in circulatingghrelin levels
induced by PD and PZ are unlikely to mediate the cholinergic
influence on GH secretion. (J Clin Endocrinol Metab 89:
2429–2433, 2004)
GHRELIN IS A 28-amino-acid peptide predominantlyproduced by the stomach, although its expression has
also been demonstrated inmany other central and peripheral
endocrine and nonendocrine tissues (1–4). Acylated ghrelin
displays strong GH-releasing activity mediated by the acti-
vation of the GH secretagogue receptor 1a (3, 5) that is ex-
pressed in the hypothalamus-pituitary unit but also in other
central and peripheral tissues (1–3, 5). Ghrelin has other
activities including: 1) stimulation of lactotroph and corti-
cotroph secretion and inhibitory influence on the gonadal
axis; 2) orexant activity coupled with control of energy ex-
penditure; 3) influence on sleep and behavior; 4) control of
gastric motility and acid secretion; 5) influence on the exo-
crine and endocrine pancreatic function as well as on glucose
metabolism; 6) cardiovascular actions; and 7) influence on
cell proliferation (3, 4, 6, 7).
Secretion of ghrelin, mostly represented by its unacylated
form that has no endocrine activities (8), reflects gastric pro-
duction and shows remarkable variations throughout the
day (9–11) that have not been confirmed by a more recent
study (12). Ghrelin secretion seems gender dependent, at
least in adulthood when ghrelin levels are higher in women
than in men; on the other hand, although a reduction of
circulating morning ghrelin levels in aging has been re-
ported, it is still unclear whether age is a critical determinant
of ghrelin secretion (12–15). Circulating ghrelin levels are
negatively associated with body mass index (BMI); in fact,
ghrelin secretion is increased in anorexia and cachexia, re-
duced in obesity, and normalized by recovery of ideal body
weight (11, 14–16). Thus, ghrelin changes in response to
variations in the nutritional state are opposite those of leptin,
and it has been suggested that both hormones act as signals
of the metabolic balance and manage the neuroendocrine
and metabolic response to starvation (3, 10).
In humans, circulating ghrelin levels are increased by fast-
ing and energy restriction and decreased by food intake (10,
16), indicating that ghrelin secretion mainly undergoes a
metabolic control. Ghrelin secretion is decreased by either iv
or oral glucose load as well as during an euglycemic hyper-
insulinemic clamp and even during insulin-induced hypo-
glycemia (4, 17–22). The inhibitory influence of overexposure
to insulin on ghrelin secretion agrees with the strong nega-
tive association between ghrelin and insulin levels that had
been predicted by the negative correlation between ghrelin
levels and BMI (10, 13, 15, 20). Whether insulin and glucose
per se play a direct or indirect inhibitory role on ghrelin
secretion is, however, still a matter of debate (23–25).
The most remarkable inhibitory input on ghrelin secretion
is represented by the activation of somatostatin (SS) receptors
as indicated by evidence that native SS, its natural analog
cortistatin, and a synthetic analog such as octreotide lower
circulating ghrelin levels in humans (12, 26–28).
The cholinergic system plays a major role in regulating
gastroenteropancreatic functions including insulin secretion,
as well as hypothalamus-pituitary actions, particularly in-
cluding GH secretion in humans as well as in animals (29–
31). The stimulatory influence ofmuscarinic receptors onGH
secretion is likely to bemediated by the negative modulation
of hypothalamic SS release (30, 31); nevertheless, unlike the
Abbreviations: BMI, Body mass index; CV, coefficient(s) of variation;
PD, pyridostigmine; PZ, pirenzepine; SS, somatostatin.
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GH response to GHRH, the somatotroph response to ghrelin
is basically refractory to both cholinergic agonists and an-
tagonists (32).
A functional relationship between the cholinergic system
and ghrelin secretion has already been demonstrated. In rats,
truncal vagotomy has been reportedly able to induce mild
reduction of stomach ghrelin mRNA levels but also to in-
crease plasmaghrelin levels approximately 3-fold (33).More-
over, it has been shown that acetylcholine mediates some
ghrelin actions in rats, e.g. stimulation of gastric contractility
and acid secretion as well as the orexigenic activity (34–36).
More recently, the peculiar suppression of ghrelin secre-
tion after feeding in sheep is reverted by atropine, a mus-
carinic receptor antagonist, and hexamethonium, a nicotinic
receptor antagonist, respectively, whereas metoclopramide,
used as an indirect cholinergic agonist, was devoid of any
effect (37). On the other hand, the food deprivation-induced
elevation in plasma ghrelin levels in rats has been found
abolished by subdiaphragmatic vagotomy and substantially
reduced by atropine (38).
To clarify whether and how acetylcholine regulates ghre-
lin secretion in humans, we studied the effects of either
pirenzepine (PZ), amuscarinic antagonist, or pyridostigmine
(PD), a cholinesterase inhibitor, on ghrelin secretion in
healthy young volunteers. In all the subjects, GH, insulin,
and glucose levels after PZ or PD administration were also
evaluated.
Subjects and Methods
Six healthy young male volunteers [age (mean  sem), 28.9  2.9 yr;
BMI, 23.6 0.8 kg/m2] were studied. All the subjects gave their written
informed consent to participate to the study, which had been approved
by an independent ethical committee.
All the subjects underwent the following three testing sessions in
random order at least 5 d apart: 1) saline; 2) PD [120mg per os (bymouth)
at time 0 min]; and 3) PZ (100 mg per os at time 0 min).
After overnight fasting, the tests were begun in the morning at 0830–
0900 h, 30 min after an indwelling catheter had been placed into an
antecubital vein of the forearm kept patent by slow infusion of isotonic
saline.
Blood samples were taken at time 0 min and every 15 min from time
45 min up to180 min. Ghrelin, GH, insulin, and glucose levels were
assayed at each time point in all the sessions.
Ghrelin levels (ng/liter) were measured in duplicate, after extraction
in reverse phase C18 columns, by RIA (Phoenix Pharmaceutical, Inc.,
Belmont, CA). Sensitivity was 30 pg/tube; the intraassay coefficient of
variation (CV) range was 0.3–10.7%.
GH levels (g/liter) were measured in duplicate by immunoradio-
metric assay (hGH-CTK, Sorin Biomedica Cardio, Saluggia, Italy). Sen-
sitivity was 0.15 g/liter; the inter- and intraassay CV ranges were
2.9–4.5% and 2.4–4.0%, respectively.
Insulin levels (mU/liter) were measured in duplicate by immuno-
radiometric assay (INSIK-5, Sorin). Sensitivity was 2.5  0.3 mU/liter;
the inter- and intraassay CV ranges were 6.2–10.8% and 5.5–10.6%,
respectively.
Glucose levels (mg/dl) were measured by glucooxidase colorimetric
method (GLUCOFIX, A. Menarini Diagnostics, Florence, Italy).
All samples from an individual subject were analyzed together.
The hormonal responses are expressed as change in area under curves
calculated by trapezoidal integration or as percent variations vs. base-
line. The statistical analysis was carried out using nonparametric
ANOVA (Friedman test) and then Wilcoxon test, as appropriate. The
results are expressed as mean  sem.
Results
Ghrelin, GH, insulin, and glucose levels did not signifi-
cantly change during saline administration (Figs. l and 2).
PD administration induced a significant increase of GH
levels (change in area under curves, 790.9  229.3 gmin/
liter; P  0.05 vs. placebo), with GH peak occurring at the
time point105 min. On the other hand, no significant vari-
ation in insulin and glucose levels was recorded after PD
administration (Fig 1).
PZ administration did not significantly modify either GH
or insulin and glucose levels (Fig. 2).
Ghrelin secretion was modified by either cholinergic en-
hancement or muscarinic blockade.
PD administration induced a clear increase in ghrelin lev-
els (11,290.5 6,688.7 pgmin/ml; P 0.05) that reached the
peak at time 120 min (about 30% above baseline) (Fig. 1).
Thus, the PD-induced ghrelin peak followed that of GH.
On the other hand, PZ administration induced clear inhi-
bition of ghrelin levels (23,205.0 8,959.5 pgmin/ml; P
0.01). Ghrelin levels underwent a progressive decrease from
time45min up to the end of the testing session (Fig. 2). The
FIG. 1. Mean (SEM) GH, insulin, glucose, and ghrelin variations
after PD administration (120 mg per os at time 0 min).
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decrease in circulating ghrelin levels after PZwas 37% below
baseline.
Side effects
In three subjects, after PD administration, mild abdominal
pain and muscle fasciculation were observed. In two sub-
jects, after PZ administration, mouth dryness and impair-
ment of visual accommodation were observed.
Discussion
The present study demonstrates that ghrelin secretion in
humans is stimulated by a cholinergic agonist such as PDand
inhibited by a muscarinic receptor blocker such as PZ. Nei-
ther PD- nor PZ-induced variations in circulating ghrelin
levels are associated with changes in insulin and glucose
levels. Moreover, the PD-induced ghrelin increase does not
precede the GH response to the enhancement of the cholin-
ergic tone elicited by the cholinesterase inhibitor.
Circulating ghrelin levels mostly reflect gastric secretion,
as demonstrated by evidence that they are reduced by 80%
after gastrectomy (16). It has been clearly demonstrated that
ghrelin secretion is increased by fasting and energy restric-
tion and reduced by food intake aswell as by glucose, insulin,
and SS (3, 4, 7, 10, 12, 14, 17, 21, 22, 26–28). Recent studies
suggested also that peptide YY and oxyntomodulin would
exert an inhibitory action on ghrelin secretion because its
circulating levels have been found reduced under chronic
treatment with peptide YY (3–36) and oxyntomodulin in
humans (39, 40). Thus, although we know of several factors
able to inhibit ghrelin secretion, so far, we know only con-
ditions (e.g. fasting and energy restriction) but not single
factors able to increase ghrelin levels.
Acetylcholine is a neurotransmitter playing amajor role in
the control of gastroenteropancreatic exocrine and endocrine
secretions (29, 41). Moreover, it had been recently empha-
sized that the cholinergic system and ghrelin secretion are
likely to be linked by a functional relationship (33, 37).
Some major ghrelin actions, such as the stimulation of
gastric contractility and acid secretion as well as the orexi-
genic activity, are mediated by the cholinergic system in rats
(34–36, 38). On the other hand, in humans, the endocrine
actions of acylated ghrelin (influence on GH, prolactin,
ACTH, and insulin) are refractory to both cholinergic ago-
nists and antagonists (32).
Regarding the potential role of acetylcholine in the regu-
lation of ghrelin secretion, mild inhibition of stomach ghrelin
mRNA levels, coupled with an increase in plasma ghrelin
levels, have been observed after truncal vagotomy in rats
(33). In sheep, the food-induced decrease in ghrelin levels has
been found reverted by atropine, a muscarinic receptor an-
tagonist, and hexamethonium, a nicotinic receptor antago-
nist, respectively; in the same study, metoclopramide, used
as an indirect cholinergic agonist, was devoid of any effect
(37).
The present study shows that muscarinic antagonism by
PZ inhibits, whereas cholinergic enhancement by PD aug-
ments ghrelin secretion in humans. Thus, these findings are
the first to demonstrate that ghrelin secretion in humans is
undermajor stimulatory control by acetylcholine, mainly via
a muscarinic mechanism.
Our present data disagree with those in sheep (see above),
indicating an inhibitory role of acetylcholine on ghrelin se-
cretion. However, our findings fit well with other data (33)
and particularly with recent evidence that a food-induced
increase in ghrelin secretion in rats is completely prevented
by supradiaphragmatic vagotomy and substantially reduced
by atropine (38). Species-specific differences would explain
this discrepancy; in fact, peculiar cholinergic regulation has
been demonstrated already in sheep that also shows peculiar
ghrelin response to energy restriction (37).
Thus, it seems clear that, at least in humans as well as in
rats, acetylcholine plays a stimulatory role on ghrelin
secretion.
In our study, the degree of ghrelin inhibition observed
under muscarinic blockade by PZ was remarkable (30%)
and similar to that recorded after hyperglycemia or during
euglycemic-hyperinsulinemic clamp (18, 19, 21, 22). The
most important inhibitory influence on ghrelin secretion re-
ported so far is, however, that exerted by the activation of SS
receptors by native SS as well as by its natural and synthetic
analogs (12, 26–28, 42). The inhibitory somatostatinergic in-
fluence is likely to take place directly at the gastric level,
FIG. 2. Mean (SEM) GH, insulin, glucose, and ghrelin variations
after PZ administration (100 mg per os at time 0 min).
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where SS receptors have been demonstrated (43). On the
other hand, SS expression and release are under stimulatory
influence by ghrelin (44), suggesting a feedback link between
these two hormones. Because acetylcholine and SS are, in
turn, linked by a functional feedback link in which acetyl-
choline negatively modulates SS secretion (29–31), this pic-
ture suggests that the cholinergic influence on ghrelin se-
cretion would be theoretically mediated by SS inhibition.
Although ghrelin is reportedly likely to be involved in the
control of insulin secretion and glucose metabolism (3, 4, 33,
45), in the present study, ghrelin increase and decrease trig-
gered by PD and PZ, respectively, were not associated with
any change in insulin and glucose levels. The influence of
ghrelin on insulin and glucose levels has generally been
observed after acute administration of acylated ghrelin at a
pharmacological dose (45). Here, we measured total circu-
lating ghrelin levels; thus, we are not able to distinguish
between the acylated and unacylated circulating forms (46)
and cannot speculate on the levels of octanoylated ghrelin
that is considered the biologically active form (2, 8). It re-
mains that, within the range of variations in circulating
ghrelin levels induced by cholinergic enhancement or block-
ade, there was no association with insulin levels that have
been demonstrated to be negatively correlated with ghrelin
secretion (4, 14). On the other hand, the positive influence of
acetylcholine on insulin secretionmostly takes place in terms
of amplification of the insulin response to secretagogues or
has been described as a direct action on pancreatic -cells
(29). Thus, the lack of any significant insulin response to
cholinergic enhancement by PD or blockade by PZ in the
present study agrees with other reports in literature (29).
Finally, we confirm the well-known stimulatory effect of
PD on GH secretion (47); this GH increase was not preceded
by the PD-induced increase in ghrelin levels. This finding
would suggest that the stimulatory effect of acetylcholine on
somatotroph function is not mediated by ghrelin and re-
mains better explained by the negative modulation of hy-
pothalamic SS release (30, 31). Indeed, in the present study,
PZ did not significantly reduce basal GH secretion, but this
agrees with studies showing that M1 muscarinic blockade
inhibits activated GH secretion only (30, 31).
The physiological relevance of a functional link between
ghrelin and somatotroph secretion is still unclear. On one
hand, a positive association between GH and ghrelin secre-
tion in obesity and anorexia and evidence that the fasting-
induced GH increase is preceded by an increase in ghrelin
secretion have been reported (3, 22, 48). On the other hand,
insulin-induced hypoglycemia as well as arginine stimulate
GH secretion, despite any stimulatory effect on ghrelin levels
(20, 49). Daily ghrelin secretion is not strictly correlated with
GH secretion and is unchanged during infusion of a GHRH
antagonist that markedly inhibits GH secretion (12). More-
over, the ghrelin knockout mouse is not dwarf and not an-
orectic as well (50).
Once again, it must be emphasized that our present data
describe the response of total circulating ghrelin levels to
cholinergic manipulations. In the absence of any information
about the levels of the acylated active form of ghrelin, we
cannot definitely rule out the possibility that it is, at least
partially, involved in the mechanisms underlying the stim-
ulatory effect of acetylcholine on somatotroph secretion.
In conclusion, this study for the first time demonstrates
that ghrelin secretion in humans is under the stimulatory
control of the cholinergic, namelymuscarinic, receptors. Ace-
tylcholine is therefore the first stimulatory neurotransmitter
shown to play a stimulatory role on ghrelin secretion in
humans.
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